Searched for
ABBOTT STAKE SALE
Trump’s more than 3,700 trades astonish Wall Street insiderPresident Trump's latest financial disclosures reveal over 3,700 trades totaling tens of millions of dollars in the first quarter. These tr...- Buy Abbott India, target price Rs 31,420: Axis SecuritiesAxis Securities recommends buying Abbott India Ltd. with a target price of Rs 31,420. The pharmaceutical company reported a 24% rise in fou...
- Buy Abbott India, target price Rs 25243 : Sharekhan by BNP ParibasAbbott India, incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 42545.46 Crore) operating in Pharmaceuticals...
- Buy Abbott India, target price Rs 22400: Axis SecuritiesAbbott India Ltd., incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 42232.99 Crore) operating in Pharmaceut...
- Buy Abbott India, target price Rs 18497: ICICI SecuritiesAbbott India Ltd., incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 34113.31 Crore) operating in Pharmaceut...
- Buy Abbott India, target price Rs 19,314: ICICI SecuritiesAbbott India Ltd., incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 36080.25 Crore) operating in Pharmaceut...
- Buy Abbott India, target price Rs 19,200: Centrum BrokingAbbott India Ltd., incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 35018.85 Crore) operating in Pharmaceut...
- Buy Abbott India, target price Rs 17,636: ICICI SecuritiesAbbott India Ltd., incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 32362.69 Crore) operating in Pharmaceut...
- Outperformer rating for Abbott India, target price Rs 18,130: CLSAThe lockdown will limit near-term growth, said CLSA, cutting FY21-FY22 EPS estimates by 9-11 per cent.
- Trending stocks: Abbott India share price climbs nearly 1%Shares of Abbott India Ltd. traded 0.63 per cent up in trade at 10:50AM on Tuesday .
- Piramal enterprises looks to sell 20% equity in healthcare businessPEL wants to accelerate growth for its healthcare division through acquisitions that will expand its portfolio of products, offer opportuni...
- Danone, HUL, KKR vie for GSK’s consumer businessAs per Monday’s market value, 72 per cent of GSK is worth around Rs 17,980 crore.
- Unichem Laboratories jumps on report of sale plansUnichem is exploring a sale of its domestic formulations business, and its proposal "is being studied" by private equity firms and strategi...
- New caveat in drug FDI policy worries MNCsValuations of Indian pharmaceutical companies may drop with the government deciding to bar non-compete clauses in takeovers by foreign comp...
- Adani Port gains over 13% on Abbott stake sale planAdani Ports and SEZ Ltd surged over 13 per cent a day after the company said it will sell a majority stake in Australia's Abbot Point port ...
- Shriram Transport Finance gains 2% on TPG’s stake sales talksSTFL surged over 2% following reports that Piramal Group is in advanced talks to buy TPG Capital's 20.27% stake in STFL.
- Sanofi-Aventis in advanced talks to buy majority stake in Universal Medicare to scale up OTC biz in IndiaAccording to a person close to the deal, Sanofi-Aventis may buy a majority stake or key brands valuing the Indian company at around Rs 450 ...
- Cipla promoters in sale talks with global firmsThe promoters of Cipla are in negotiations to sell their stake to a global buyer, according to investment banking sources familiar with the...
- Abbott to pay 17K crore for Piramal generics businessThe American company has valued a part of the Piramal business built over two decades of acquisition at more than nine times its sales, exc...
- Wockhardt taps MNCs to sell Protinex, FarexIn a move to prune its debts, troubled pharma firm Wockhardt is in talks with a few MNCs to sell two of its best-selling brands - Protinex ...
Load More
